Patent US5455158A successfully refreshed from Google Patents.
← Back to Patent Explorer
US5455158A Expired / Lapsed US ⏱️ 0.0 years remaining

Fibrin binding domain polypeptides and uses and methods of producing same

Assignee: Savient Pharmaceuticals Inc
•
Filing: 1993-05-04
•
Granted: 1995-10-03
•
Expires: 2013-05-04
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract This invention provides an imaging agent which comprises a polypeptide labeled with an imageable marker, such polypeptide having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin. The invention further provides a method wherein the imaging agent is used for imaging a fibrin-containing substance, i.e., a thrombus or atherosclerotic plaque. Further provided are plasmids for expression of polypeptides having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin, hosts containing these plasmids, methods of producing the polypeptides, methods of treatment using the polypeptides, and methods of recovering, refolding and reoxidizing the polypeptides. The invention also provides for purified polypeptides substantially free of other substances of human origin which have an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and which are capable of binding to fibrin.

Inventors

  • 👤 Tikva Vogel
  • 👤 Avigdor Levanon
  • 👤 Moshe M. Werber
  • 👤 Rachel Guy
  • 👤 Amos Panet

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-02 10:24
CPC Classifications
A; A61; A61K; A61K49/00; A61K49/0004; A61K49/0008; A61K47/00; A61K47/50; A61K47/51; A61K47/62; A61K47/64; A61K47/6415; A61K49/0002; A61K51/00; A61K51/02; A61K51/04; A61K51/08; A61K51/082; A61K51/088; A61M; A61M25/00; A61M25/0043; A61M25/0045; C; C07; C07K; C07K1/00; C07K1/107; C07K1/113; C07K1/1133; C07K14/00; C07K14/195; C07K14/315; C07K14/3153; C07K14/435; C07K14/78; C07K19/00; C07K7/00; C07K7/04; C07K7/06; A61K2123/00; A61K38/00; C07K2319/00; C07K2319/33

Claims Analysis

Total Claims: 9
Claim 1
Independent Claim 95 words
A method for imaging a fibrin-containing substance which comprises contacting the fibrin-containing substance to be imaged with an imaging agent under conditions such that the imaging agent binds to fibrin in the fibrin-containing substance, imaging bound imaging agent, and thereby imaging the fibrin-containing substance, wherein the imaging agent comprises a polypeptide labeled with an imageable marker, wherein the polypeptide is a 12 kD polypeptide corresponding to an amino acid sequence present in the fibrin binding domain of naturally-occurring human fibronectin and comprising the amino acid sequence of amino acids 1-109 as shown in FIG. 1.
Claim 2
Independent Claim 95 words
A method for imaging a fibrin-containing substance which comprises contacting the fibrin-containing substance to be imaged with an imaging agent under conditions such that the imaging agent binds to fibrin in the fibrin-containing substance, imaging bound imaging agent, and thereby imaging the fibrin-containing substance, wherein the imaging agent comprises a polypeptide labeled with an imageable marker, wherein the polypeptide is a 12 kD polypeptide corresponding to an amino acid sequence present in the fibrin binding domain of naturally-occurring human fibronectin and comprising the amino acid sequence of amino acids 1-109 as shown in FIG. 1.
Claim 3
Dependent Claim 12 words
A method of claim 1, wherein the fibrin-containing substance is a thrombus.
Claim 4
Dependent Claim 12 words
A method of claim 1, wherein the fibrin-containing substance is atherosclerotic plaque.
Claim 5
Dependent Claim 49 words
The method according to claim 1 wherein the fibrin-containing substance is within blood vessels of a subject and wherein contacting is performed by administering the imaging agent contained in a suitable carrier to the subject under conditions permitting the imaging agent to enter the blood vessels of the subject.
Claim 6
Dependent Claim 12 words
A method of claim 4, wherein the fibrin-containing substance is a thrombus.
Claim 7
Dependent Claim 12 words
A method of claim 4, wherein the fibrin-containing substance is atherosclerotic plaque.
Claim 8
Dependent Claim 23 words
A method of claim 1, wherein the marker is a radioactive isotope, an element which is opaque to X-rays, or a paramagnetic ion.
Claim 9
Dependent Claim 15 words
A method of claim 1, wherein the imaging is carried out using a gamma camera.

References Cited (Backward Citations)

US4315906A Cited
EP0207751B1 Cited
US5026537A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1998-10-02 1999-04-03 1999-10-03 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2002-10-02 2003-04-03 2003-10-03 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2006-10-02 2007-04-03 2007-10-03 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag